Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GSK3B | P49841 | 8/20 | 1.00 |
| ▸ | BACE1 | P56817 | 8/20 | 1.00 |
| ▸ | TLR9 | Q9NR96 | 1/20 | 1.00 |
| ▸ | F3 | P13726 | 4/20 | 0.73 |
| ▸ | TYR | P14679 | 3/20 | 0.73 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.73 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.73 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.73 |
| ▸ | FOS | P01100 | 1/20 | 0.70 |
| ▸ | JUN | P05412 | 1/20 | 0.70 |
| ▸ | AKR1B10 | O60218 | 2/20 | 0.64 |
| ▸ | AKR1B1 | P15121 | 2/20 | 0.64 |
| ▸ | PKM | P14618 | 2/20 | 0.64 |
| ▸ | CA12 | O43570 | 2/20 | 0.64 |
| ▸ | CA1 | P00915 | 2/20 | 0.64 |
| ▸ | CA2 | P00918 | 2/20 | 0.64 |
| ▸ | CA7 | P43166 | 2/20 | 0.64 |
| ▸ | CA9 | Q16790 | 2/20 | 0.64 |
| ▸ | CA14 | Q9ULX7 | 2/20 | 0.64 |
| ▸ | ESR1 | P03372 | 1/20 | 0.64 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL609968 | 1.00 | GSK3B (1.00) | GSK3BBACE1TLR9F3TYR | |
| SCHEMBL13311574 | 0.94 | GSK3B (0.89) | GSK3BBACE1TLR9F3TYR | |
| SCHEMBL15290855 | 0.91 | FOS (0.87) | GSK3BBACE1TLR9F3TYR | |
| SCHEMBL3825969 | 0.86 | GSK3B (0.75) | GSK3BBACE1TLR9F3TYR | |
| SCHEMBL3825974 | 0.86 | GSK3B (0.75) | GSK3BBACE1TLR9F3TYR | |
| SCHEMBL3825972 | 0.86 | GSK3B (0.75) | GSK3BBACE1TLR9F3TYR | |
| SCHEMBL3580956 | 0.85 | TYR (1.00) | GSK3BBACE1TLR9F3TYR | |
| SCHEMBL2198475 | 0.85 | TYR (1.00) | GSK3BBACE1TLR9F3TYR | |
| SCHEMBL2146080 | 0.85 | TYR (1.00) | GSK3BBACE1TLR9F3TYR | |
| SCHEMBL23260255 | 0.85 | GSK3B (0.73) | GSK3BBACE1TLR9F3TYR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 89 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11839637-B2 | Neuron activator | KINJIRUSHI CO., LTD. (JP) | 2023-12-12 | — | — | US | disclosed |
| US-20230190856-A1 | COMPOSITION COMPRISING A COMPLEX COMPRISING A CURCUMINOID COMPOUND, AND STEVIOL GLYCOSIDES OR A LICORICE EXTRACT OR A FRACTION THEREOF, AND USES THEREOF | KOREA RESEARCH INSTITUTE OF BIOSCIENCE AND BIOTECHNOLOGY (KR) | 2023-06-22 | — | — | US | disclosed |
| US-20230190856-A1 | COMPOSITION COMPRISING A COMPLEX COMPRISING A CURCUMINOID COMPOUND, AND STEVIOL GLYCOSIDES OR A LICORICE EXTRACT OR A FRACTION THEREOF, AND USES THEREOF | KOREA RESEARCH INSTITUTE OF BIOSCIENCE AND BIOTECHNOLOGY (KR) | 2023-06-22 | — | — | US | disclosed |
| US-11596716-B2 | Compounds and matrices for use in bone growth and repair | HUMAN BIOMOLECULAR RESEARCH INSTITUTE (US) | 2023-03-07 | — | — | US | disclosed |
| US-20230000940-A1 | Composition for prevention or treatment of Porcine epidemic diarrhea virus infection comprising curcuminoid and licorice extracts or fraction thereof | KOREA RESEARCH INSTITUTE OF BIOSCIENCE AND BIOTECHNOLOGY (KR) | 2023-01-05 | — | — | US | disclosed |
| US-20220152001-A1 | HUMAN THERAPEUTIC AGENTS | ANKH LIFE SCIENCES LIMITED (IE) | 2022-05-19 | — | — | US | disclosed |
| US-20210299199-A1 | Neuron activator | KINJIRUSHI CO., LTD. (JP) | 2021-09-30 | — | — | US | disclosed |
| US-11065288-B2 | Neuron activator | KINJIRUSHI CO., LTD. (JP) | 2021-07-20 | — | — | US | disclosed |
| US-20210138117-A1 | COMPOUNDS AND MATRICES FOR USE IN BONE GROWTH AND REPAIR | HUMAN BIOMOLECULAR RESEARCH INSTITUTE (US) | 2021-05-13 | — | — | US | disclosed |
| WO-2021080388-A1 | COMPOSITION FOR PREVENTING OR TREATING PORCINE EPIDEMIC DIARRHEA VIRUS INFECTION, COMPRISING COMPLEX CONTAINING CURCUMINOID-BASED COMPOUND AND LICORICE EXTRACT OR FRACTION THEREOF | 한국생명공학연구원 | 2021-04-29 | — | — | WO | disclosed |
| US-7507864-B2 | Method for the synthesis of curcumin analogues | SALISBURY UNIVERSITY (US) | 2009-03-24 | — | — | US | disclosed |
| WO-2008048410-A9 | DIAGNOSTIC METHODS AND GENETIC MARKERS FOR ALZHEIMER DISEASE | HUMAN BIOMOLECULAR RES INST (US) | 2008-06-26 | — | — | WO | disclosed |
| WO-2008048410-A2 | DIAGNOSTIC METHODS AND GENETIC MARKERS FOR ALZHEIMER DISEASE | HUMAN BIOMOLECULAR RESEARCH INSTITUTE (US) | 2008-04-24 | — | — | WO | disclosed |
| US-20080085932-A1 | Pharmaceutical Compositions Useful In Prevention and Treatment of Beta-Amyloid Protein-Induced Disease | KIM DARRICK S | 2008-04-10 | — | — | US | disclosed |
| US-20080033055-A1 | Method for the Synthesis of Curcumin Analogues | SALISBURY UNIVERSITY | 2008-02-07 | — | — | US | disclosed |
| US-20080033055-A1 | Method for the Synthesis of Curcumin Analogues | SALISBURY UNIVERSITY | 2008-02-07 | — | — | US | disclosed |
| US-20070141183-A1 | Curcuminoid compositions exhibiting synergistic inhibition of the expression and/or activity of cyclooxygenase-2 | METAPROTEOMICS, LLC (CA) | 2007-06-21 | — | — | US | disclosed |
| US-20070060644-A1 | Therapeutic curcumin derivatives | STC.UNM | 2007-03-15 | — | — | US | disclosed |
| US-20070060644-A1 | Therapeutic curcumin derivatives | STC.UNM | 2007-03-15 | — | — | US | disclosed |
| US-20070003641-A1 | Synergistic pharmaceutical compositions useful in prevention and treatment of beta-amyloid protein-induced disease | KIM DARRICK S H | 2007-01-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (12 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11596716-B2 | Compounds and matrices for use in bone growth and repair | BMP2, BMP4, BMP6 | GSK3B 918/4885BACE1 2083/4885TLR9 2565/4885 |
| US-20080033055-A1 | Method for the Synthesis of Curcumin Analogues | APP, PSEN1, SQLE | GSK3B 2652/4885BACE1 5/4885TLR9 4482/4885 |
| US-20070003641-A1 | Synergistic pharmaceutical compositions useful in prevention and treatment of beta-amyloid protein-induced disease | APP, BACE1, GSAP | GSK3B 222/4885BACE1 2/4885TLR9 4525/4885 |
| US-20230190856-A1 | COMPOSITION COMPRISING A COMPLEX COMPRISING A CURCUMINOID COMPOUND, AND STEVIOL GLYCOSIDES OR A LICORICE EXTRACT OR A FRACTION THEREOF, AND USES THEREOF | CD4, IFNG, CD14 | GSK3B 1132/4885BACE1 1151/4885TLR9 177/4885 |
| US-20070060644-A1 | Therapeutic curcumin derivatives | FABP2, GLS2, FABP1 | GSK3B 2812/4885BACE1 750/4885TLR9 1582/4885 |
| US-11065288-B2 | Neuron activator | BDNF, DBH, CHAT | GSK3B 2892/4885BACE1 92/4885TLR9 2925/4885 |
| US-20080085932-A1 | Pharmaceutical Compositions Useful In Prevention and Treatment of Beta-Amyloid Protein-Induced Disease | APP, BACE1, PSEN1 | GSK3B 39/4885BACE1 2/4885TLR9 4876/4885 |
| US-20210138117-A1 | COMPOUNDS AND MATRICES FOR USE IN BONE GROWTH AND REPAIR | BMP2, BMP4, BMP6 | GSK3B 918/4885BACE1 2083/4885TLR9 2565/4885 |
| US-20230000940-A1 | Composition for prevention or treatment of Porcine epidemic diarrhea virus infection comprising curcuminoid and licorice extracts or fraction thereof | CUL3, PIGS, PYCARD | GSK3B 289/4885BACE1 3490/4885TLR9 2447/4885 |
| US-20220152001-A1 | HUMAN THERAPEUTIC AGENTS | INMT, HNMT, HASPIN | GSK3B 2563/4885BACE1 1295/4885TLR9 3320/4885 |
| US-20210299199-A1 | Neuron activator | BDNF, DBH, CHAT | GSK3B 2892/4885BACE1 92/4885TLR9 2925/4885 |
| US-11839637-B2 | Neuron activator | BDNF, DBH, CHAT | GSK3B 2892/4885BACE1 92/4885TLR9 2925/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.